Profile data is unavailable for this security.
About the company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
- Revenue in USD (TTM)10.00k
- Net income in USD-49.70m
- Incorporated2016
- Employees24.00
- LocationARS Pharmaceuticals Inc11682 El Camino Real, Suite 120SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 771-9307
- Fax+1 (845) 818-3588
- Websitehttps://ars-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | 0.00 | -80.60m | 820.01m | 74.00 | -- | 2.42 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 824.02m | 110.00 | -- | 5.24 | -- | 105.04 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 827.29m | 116.00 | -- | 2.22 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 838.75m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 850.74m | 168.00 | -- | -- | -- | 20.97 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 855.42m | 158.00 | -- | 1.96 | -- | 3,449.28 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Immunome Inc | 12.68m | -232.03m | 864.75m | 55.00 | -- | 3.01 | -- | 68.18 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 865.27m | 24.00 | -- | 3.85 | -- | 86,527.46 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 872.05m | 180.00 | -- | 3.30 | -- | 7.00 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 874.92m | 116.00 | -- | -- | -- | -- | -0.1622 | -0.197 | -0.0009 | -- | -- | -- | -- | -2,620.69 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 89bio Inc | 0.00 | -165.03m | 878.57m | 70.00 | -- | 1.67 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 894.23m | 234.00 | -- | 3.67 | -- | 1,513.08 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Humacyte Inc | 0.00 | -105.70m | 900.28m | 183.00 | -- | 34.42 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 916.33m | 284.00 | -- | -- | -- | 22.02 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Data as of May 23 2024. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD
27.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 10.86m | 11.26% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 2.95m | 3.06% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.82m | 2.93% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.36m | 2.45% |
| K2 & Associates Investment Management, Inc.as of 31 Mar 2024 | 2.22m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.60m | 1.66% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.08m | 1.12% |
| Geode Capital Management LLCas of 31 Mar 2024 | 876.67k | 0.91% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 867.32k | 0.90% |
| Rubric Capital Management LPas of 31 Mar 2024 | 639.20k | 0.66% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
